• Pazhani Sundaram, Ph.D

    Dr. Sundram has strong experience in protein expression technologies, molecular biology, biochemistry, peptidomimetics and in drug delivery systems. Prior to starting Recombinant Technologies in 1998, he was trained at Yale School of Medicine for a decade. At Yale, Dr. Sundaram contributed in the research and development of a vaccine to treat human papilloma virus in a rabbit model. This work formed the basis for Merck in developing the vaccine for HPV 16, which is currently marketed as 'Gardasil'. Dr. Sundaram's research is acknowledged on the Merck's patent for the above vaccine.

    Dr. Sundaram's research followed by a clinical trial on a herbal medicine for his doctoral thesis research translated to a marketable drug in India to treat coronary heart disease.

  • Madan Anant, D.V.M., Ph.D

    Madan Anant has more than 15 years of experience in biopharmaceutical in conducting scientific due diligence on business prospects for M&A. and managing and executing product discovery and development projects. In Clinical Data, Inc., where he was a Director, he evaluated multiple business development opportunities on biomarkers and therapeutics for their scientific strength, clinical value and the commercial potential, and managed strategic alliance projects.

    Currently, Dr. Anant has been assisting diverse companies in M&A and on a variety of product development initiatives. Madan did his post-doctoral training at Yale University and received his Ph.D. from the Indian Institute of Science, Bangalore, India.

  • Ranjini Sundaram, Ph.D

    Dr. Ranjini Sundaram, Ph.D. has been actively involved in developing the AmyTrap technology. She is a co-inventor of Amytrap patent. Her contributions have immensely helped RT to move AmyTrap from inception to the current stage of development. She is employed as a Research Faculty at Yale University School of Medicine, and has been consulting RT.

    Her research prior to Yale includes research at two companies including RTneurodegenerative diseases like Alzheimer's disease and Neimann Pick, Type C. Her expertise in protein chemistry, molecular biology and immunology, and her working knowledge in running clinical trials at the Yale Cancer Center and regulatory affairs are valuable assets to RT.